Preoperative Management and Preparation for Transfusion-Free Surgery

Transfusion-Free Medicine and Surgery

Volumn , Issue , 2007, Pages 60-74

  Goodnough, Lawrence T ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Darbopoietin alfa; Erythropoietin therapy; Iron therapy; Red cell mass; Transfusion free surgery

Indexed keywords

EID: 84889613297     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470994788.ch3     Document Type: Chapter

References (71)

1. Circular of information for the use of human blood and blood components. American Association of Blood Banks, America's Blood Centers, and American Red Cross. 2000.
2. Wittmann PH, Wittmann FW. Total hip replacement surgery without blood transfusion in Jehovah's Witnesses. Br J Anaesth 1992; 68: 306-7.
3. Helm RE, Rosengart TK, Gomez M et al. Comprehensive multimodality blood conservation: 100 consecutive CABG operations without transfusion. Ann Thorac Surg 1998; 65: 125-36.
4. Smoller BR, Kruskall MS. Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements. N Engl J Med 1986; 314: 1233-5.
5. Brecher ME, Goodnough LT. The rise and fall of preoperative autologous blood donation. Transfusion 2001; 41: 1459-62.
6. Goodnough LT, Brecher ME, Kanter MH, Aubuchon JP. Transfusion medicine Part II: blood conservation. N Engl J Med 1999; 340: 525-33.
7. Goldman M, Savard R, Long A, Gelinas S, Germain M. Declining value of preoperative autologous donation. Transfusion 2002; 42: 819-23.
8. Forgie M, Wells P, Laupacis A, Fergusson D. Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red cell transfusion: results of a meta analysis. International Study of Perioperative Transfusion (ISPOT) Investigators. Arch Intern Med 1998; 158: 610-16.
9. Krombach J, Kampe S, Gathof BS, Kiefenbach C, Kasper SM. Human error, the persisting risk of blood transfusion: a report of five cases. Anesth Analg 2002; 94: 154-6.
10. Hutchinson AB, Fergusson D, Graham ID, Laupacis A, Herrin J, Hillyer CD. Utilization of technologies to reduce allogeneic blood transfusion in the United States. Transfus Med 2001; 11: 79-85.
11. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997; 336: 933-8.
12. Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron, and erythropoiesis. Blood 2000; 96: 823-33.
13. Goodnough LT, Verbrugge D, Marcus RE, Goldberg V. The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion. J Am Coll Surg 1994; 179: 171-6.
14. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Clin Med 1995; 126: 57-64.
15. Goodnough LT, Marcus RE. Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron. Vox Sang 1998; 75: 128-33.
16. Goodnough LT, Price TH, Parvin CA et al. Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy. Br J Haematol 1994; 87: 695-9.
17. Goodnough LT, Brittenham G. Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med 1990; 115: 28-35.
18. Goodnough LT, Price TH, Rudnick S. Soegiarso RW. Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy. Transfusion 1992; 32: 441-5.
19. Coleman PH, Stevens AR, Dodge HT, Finch CA. Rate of blood regeneration after blood loss. Arch Int Med 1953; 92: 341-8.
20. Crosby WH. Treatment of hemochromatosis by energetic phlebotomy: one patient's response to getting 55 liters of blood in 11 months. Br J Haematol 1958; 4: 82-8.
21. Goodnough LT, Merkel K. The use of parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture. Int J Hematol 1996; 1: 163-6.
22. Finch CA. Erythropoiesis, erythropoietin, and iron. Blood 1982; 60: 1241-6.
23. Auerbach M, Barker L, Bahrain H et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapyinduced anemia: a multicenter, open-label, randomized trial. JCO 2004; 22: 1301-7.
24. Muirhead M, Bargman J, Burgess E, Jindal KK, Levin A, Nolin L, Parfrey P. Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kid Dis 1995; 26: S1.
25. Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation and tolerance of response to iron dextran (Imferon) administered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet 1988; 26: 235.
26. Mays T, Mays T. Intravenous iron dextran therapy in the treatment of anemia occuring in surgical, gynecologic, and obstetric patients. Surg Gyn Obstet 1976; 143: 381.
27. Hamstra RD, Block MH, Schocket AL. Intravenous iron dextran in clinical medicine. JAMA 1980; 243: 1726.
28. Woodman J, Shaw RJ, Shipman AJ, Edwards AM. A surveillance program on a long-established product: Imferon (Iron Dextran BP). Pharmaceut Med 1987; 1: 289.
29. Fishbane S, Ungureanu VD, Maeska JK et al. The safety of intravenous iron dextran in hemodialysis patients. Am J Kid Dis 1996; 28: 529-34.
30. Auerbach M, Winchester J, Wahab A, Richards K, McGinley M, Hall F, Anderson J, Briefel G. A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients. Am J Kid Dis 1998; 31: 81.
31. Faich G, Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextran. Am J Kid Dis 1999; 33: 464.
32. Sunder-Plassmann G, Horl WH. Safety aspects of parenteral iron in patients with end-stage renal disease. Drug Safety 1997; 17: 241.
33. Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A. Intravenous ferric saccharate as an iron supplementation in dialysis patients. Nephron 1996; 72: 413.
34. Sunder-Plassmann G, Horl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transpl 1995; 10: 2070.
35. Nissenson AR, Lindsay RM, Swan S, Sellgman P, Strobos J. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American trial. Am J Kid Dis 1999; 33: 471.
36. Calvar C, Mata D, Alonso C, Ramos B, Lopez de Novales E. Intravenous administration of iron gluconate during haemodialysis. Nephrol Dial Transpl 1997; 12: 574.
37. Zanen AL, Adriaansen HJ, Van Bommel EFH, Posthuma R, Th. de Jong GM. "Over saturation" of transferrin after intravenous ferric glucomate (Ferrlecit) in haemodialysis patients. Nephrol Dial Transpl 1996; 11: 820.
38. Seligman PA, Schleicher RB. Comparison of methods used to measure serum iron in the presence of iron gluconate or iron dextran. Clin Chem 1999; 45: 898.
39. Pascual J, Teruel JL, Liano F, Sureda A, Ortuna J. Serious adverse reactions after intravenous ferric gluconate. Nephrol Dial Transpl 1992; 7: 271.
40. Hillman RS, Henderson PA. Control of marrow production by the level of iron supply. J Clin Invest 1969; 48: 454.
41. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood 1969; 34: 357.
42. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
43. Muirhead N. Recombinant human erythropoietin (epoietin alpha) in anemic patients on hemodialysis: Canada. In: Erslev AJ, ed. Erythropoietin. Baltimore, MD: Johns Hopkins University Press, 1991: 241-68.
44. Kaupke CJ, Butler GC, Vaziri ND. Effect of recombinant human erythropoietin on platelet production in dialysis patients. J Am Soc Nephrol 1993; 10: 1672-5.
45. Taylor JE, Henderson IS, Stewart WK et al. Erythropoietin and spontaneous platelet aggregation in heamodialysis patients. Lancet 1991; 338: 1361-2.
46. Taylor JE, Belch JJF, McLaren M et al. Effect of erythropoietin therapy and blood withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kid Int 1993; 44: 182-90.
47. Gordge MP, Leaker B, Patel A et al. Recombinant human erythropoietin shortens the uremic bleeding time without causing intravascular haemostatic activation. Thromb Res 1990; 57: 171-82.
48. Vigano G, Benigni A, Mendogni P et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kid Dis 1991; 1: 44-9.
49. Raine AEG. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications for erythropoietin therapy. Lancet 1988; 1: 97-100.
50. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoietin. N Engl J Med 1998; 339: 584-90.
51. Goodnough LT, Rudick S, Price TH et al. Increased collection of autologous blood preoperatively with recombinant human erythropoietin therapy. N Engl J Med 1989; 321: 1163-7.
52. Goodnough LT, Price TH, EPO Study Group. A phase III trial of recombinant human erythropoietin in non-anemic orthopaedic patients subjected to aggressive autologous blood phlebotomy: dose, response, toxicity, and efficacy. Transfusion 1994; 34: 66-71.
53. Price TH, Goodnough LT, Vogler W et al. The effect of recombinant erythropoietin therapy administration on the efficacy of autologous blood donation in patients with low hematocrits. Transfusion 1996; 36: 29-36.
54. Goodnough LT, Monk TG. Evolving concepts in autologous blood procurement: case reports of perisurgical anemia complicated by myocardial infarction. Am J Med 1996; 101 (2A): 33S-37S.
55. Biesma DH, Bronkhorst PJH, de Groot PG et al. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and bloood rheology in autologous blood donors. J Lab Clin Med 1994; 124: 42-7.
56. Sowade O, Ziemer S, Sowade B et al. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery. J Lab Clin Med 1997; 129: 376-83.
57. Sowade O, Warnke H, Scigalla P et al. Avoidance of allogeneic blood transfusions by treatment with epoietin beta (recombinant human erythropoietin) in patients undergoing open heart surgery. Blood 1997; 89: 411-18.
58. Sowade O, Gross J, Sowade B et al. Evaluation of oxygen availability with oxygen status algorithm in patients undergoing open heart surgery treated with epoietin beta. J Lab Clin Med 1997; 129: 97-105.
59. D'Ambra MN, Gray RJ, Hillman R et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. Ann Thorac Surg 1997; 64: 1686-93.
60. Goodnough LT, Despotis GJ, Parvin CA. Erythropoietin therapy in patients undergoing cardiac operations. Ann Thorac Surg 1997; 64: 1579-80.
61. Goodnough LT, Spence R, Shander A. Bloodless Medicine. Transfusion 2003; 43: 668-76.
62. Monk TG, Goodnough LT, Brecher ME et al. A prospective, randomized trial of three blood conservation strategies for radical prostatectomy. Anesthesiology 1999; 91: 24-33.
63. Kaisi M, Ngwalle EWK, Runyoro DE, Rogers J. Evaluation of tolerance of and response to iron dextran administered by total dose infusion to pregnant women with iron deficiency anemia. Int J Gynecol Obstet 1988; 26: 235-43.
64. Anand S, Nissenson AR. Pure red cell aplasia: an emerging epidemic in dialysis patients? Perit Dial Int 2003; 23: 317-19.
65. Lasadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75.
66. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-5.
67. Brines ML, Ghezzi P, Keenan S et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. PNAS 2000; 97: 10526-31.
68. Brezden CB, Phillips KA, Abdolell M. Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Onc 2000; 18: 2695-701.
69. Egrie JC, Browne JK. Development and characterization of novel erythropoiesisstimulating protein (NESP). Br J Cancer 2001; 84(Suppl. 1): 3-10.
70. Glaspy J, Jadeja JS, Justice G et al. A dose-finding and safety study of novel erythropoiesis-stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer 2001; 84(Suppl. 1): 17-23.
71. Smith RE, Jaiyesimi IA, Meza LA, Tchekmedylan NS, Chan D, Griffith H et al. Novel erythropoiesis-stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer 2001; 84(Suppl. 1): 24-30.